insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.

British journal of haematology 2026 Vol.208(4) p. 1424-1428

Song J, Jiang H, Ding K, Liu H, Wang Y, Gao S, Ren Y, Liu Z, Zhuo J, Li B, Wang G, Jiao Z, Gao D, Fu R

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

In this prospective, multicentre clinical trial, we evaluated zanubrutinib combined with lenalidomide, temozolomide and rituximab monoclonal antibody ± methotrexate (RLZT ± MTX) as first-line treatmen

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Song J, Jiang H, et al. (2026). Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.. British journal of haematology, 208(4), 1424-1428. https://doi.org/10.1111/bjh.70335
MLA Song J, et al.. "Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.." British journal of haematology, vol. 208, no. 4, 2026, pp. 1424-1428.
PMID 41582824
DOI 10.1111/bjh.70335

Abstract

In this prospective, multicentre clinical trial, we evaluated zanubrutinib combined with lenalidomide, temozolomide and rituximab monoclonal antibody ± methotrexate (RLZT ± MTX) as first-line treatment for primary central nervous system lymphoma. RLZT ± MTX demonstrated good efficacy and safety, especially for elderly patients who cannot undergo intensive chemotherapy.

MeSH Terms

Humans; Central Nervous System Neoplasms; Female; Male; Antineoplastic Combined Chemotherapy Protocols; Aged; Lenalidomide; Temozolomide; Middle Aged; Methotrexate; Rituximab; Pyrazoles; Prospective Studies; Pyrimidines; Piperidines; Adult; Aged, 80 and over; Lymphoma; Treatment Outcome

같은 제1저자의 인용 많은 논문 (5)